Endoscopic Pituitary Tumor Surgery

Endoscopic pituitary tumor surgery is a minimally invasive neurosurgical technique for removing pituitary adenomas and other tumors of the sellar and parasellar region through the natural nasal passages, without any external incision on the face or scalp. A thin, rigid endoscope equipped with a high-definition camera is passed through one or both nostrils, through the sphenoid sinus, and directly to the floor of the sella turcica — the bony cavity housing the pituitary gland — allowing surgeons to visualize and resect the tumor under excellent illumination and magnification.

This approach has largely replaced the older microscopic transsphenoidal technique at specialized centers, offering superior visualization of lateral recesses, the cavernous sinus interface, and suprasellar extension without the need for a nasal speculum or submucosal dissection. The goals of surgery depend on the tumor type: for functioning adenomas, hormonal normalization and potential cure; for non-functioning macroadenomas, decompression of the optic apparatus and preservation or restoration of visual function; and for all tumors, histopathological and molecular diagnosis.

Preparation for endoscopic pituitary surgery begins in the outpatient setting several weeks before the planned procedure. A comprehensive pituitary hormonal panel is obtained to identify any pre-existing hormonal deficiencies and to establish baseline values against which postoperative results can be compared. Formal visual field perimetry is performed when there is any concern about optic chiasm involvement. Nasal anatomy is assessed by CT of the sinuses to plan the surgical approach and identify any anatomical variants that may require modification. Patients should discuss their complete medication list with the team, as anticoagulants and antiplatelet medications will need to be paused before surgery. A brief nasal steroid course may be prescribed to reduce mucosal inflammation. Patients are instructed to fast from midnight on the evening before surgery.

The procedure is performed under general anesthesia, typically lasting two to four hours, though complex tumors may require longer. The surgical team works through both nostrils, using the endoscope and dedicated instruments. The sphenoid sinus is opened to expose the sella floor, which is then carefully removed. The tumor is dissected from the surrounding normal pituitary gland, optic structures, and vascular walls of the cavernous sinus with the assistance of high-definition endoscopic visualization and, in some cases, intraoperative MRI to confirm completeness of resection.

Following tumor removal, the sellar floor is reconstructed to prevent cerebrospinal fluid (CSF) leakage. Patients are typically monitored overnight and transferred to a standard ward the following day. Nasal packing, if used, is removed within a several days. Blowing the nose, heavy lifting, and straining must be avoided for several weeks to protect the surgical repair.

Endoscopic pituitary surgery is generally well tolerated, but as with any neurosurgical procedure, risks exist. The most common complications include:

• Cerebrospinal fluid (CSF) leak — occurs in a small proportion of cases and may require a second procedure for repair.
• Diabetes insipidus (DI) — temporary or permanent inability to concentrate urine, caused by disruption of antidiuretic hormone production; temporary DI is common in the first few days and usually resolves.
• Hypopituitarism — new or worsened pituitary hormonal deficiency, which may require lifelong hormone replacement.
• Meningitis — rare bacterial infection of the meninges, more common if a CSF leak occurs.
• Injury to the carotid arteries — very rare but potentially serious; experienced surgeons use neuronavigation to minimize this risk.
• Visual deterioration — rare, but can occur from direct surgical trauma or postoperative swelling near the optic nerves.

Hormonal outcomes depend on the specific adenoma type and the completeness of resection. Success rates are higher for microadenomas than for larger tumors with cavernous sinus invasion. Vision typically improves within days to weeks following decompression of the optic chiasm, with recovery of visual fields in the majority of patients presenting with preoperative deficits.

All patients require endocrine follow-up at regular intervals for at least the first year, and then annually thereafter, with MRI imaging to monitor for tumor residual or recurrence. Cortisol replacement must be managed with particular care; patients should carry emergency steroid identification and know how to increase their dose during illness. For tumors with residual disease after surgery, adjuvant treatment with stereotactic radiosurgery or medical therapy may be recommended by the multidisciplinary team.